Delving into the Latest Updates on 402-TCR with Synapse

Overview

Basic Info

Drug Type

TCR therapy

Synonyms

Anti-NY-ESO-1 TCR - T-Cure

Target

NY-ESO-1

Mechanism

NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsDigestive System DisordersUrogenital Diseases

Active Indication

Bladder CancerLiver Cancer

Inactive Indication

Ovarian Epithelial CarcinomaSarcoma

Originator Organization

T-Cure Bioscience, Inc.Startup

Active Organization

T-Cure Bioscience, Inc.Startup

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Conventional techniques for the detection of biomolecular interactions can be limited by the need for exogenous labels, time- and labor-intensive protocols, as well as by poor sensitivity levels. A refractometer instrument has been reconfigured to detect biomolecular interactions through changes in surface plasmon resonance (SPR). The binding kinetics and affinity values of anti-NY-ESO-1 monoclonal antibody, ES121, to the cancer-testis antigen NY-ESO-1 were determined according to the surface heterogeneity model and resulted in K(D) values of 1.3x10(-9) and 2.1x10(-10) M. The reconfigured instrument was then used to measure the interaction between tumor antigens and serum antibodies against these antigens in preselected cancer patient sera samples. The tumor antigens assayed included NY-ESO-1, SSX2 and p53, all used as recombinant proteins containing polyhistidine tags. These results demonstrated that the instrument is capable of detecting the binding of serum antibodies from cancer patient sera to immobilized tumor antigens, consistent with those observed previously in ELISA-based experiments. These results demonstrate the potential of SPR technology for the rapid diagnosis and monitoring immune responses.

100 Deals associated with 402-TCR

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Preclinical	US	T-Cure Bioscience, Inc.Startup	-
Liver Cancer	Preclinical	US	T-Cure Bioscience, Inc.Startup	-
Ovarian Epithelial Carcinoma	Discovery	US	T-Cure Bioscience, Inc.Startup	-
Sarcoma	Discovery	US	T-Cure Bioscience, Inc.Startup	-